Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Revenue of Embecta Corp. (EMBC)
Revenue in 2023 (TTM): $1.12 B
According to Embecta Corp.'s latest financial reports the company's current revenue (TTM) is $1.12 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Embecta Corp.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.12 B | $749.9 M | $247.8 M | $105.7 M | $70.4 M |
| 2022 | $1.13 B | $774.9 M | $393.4 M | $256.6 M | $223.6 M |
| 2021 | $1.17 B | $800 M | $530 M | $495 M | $414.8 M |
| 2020 | $1.09 B | $762.6 M | $524.1 M | $485.8 M | $427.6 M |
| 2019 | $1.11 B | $786 M | $538 M | $500 M | $432 M |